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Abstract
Antigens in modern subunit vaccines are largely soluble and poorly immunogenic proteins
inducing relatively short-lived immune responses. Appropriate adjuvants initiate early innate
immune responses, amplifying subsequent adaptive immune responses. Agonists of TLR2 are
devoid of significant pro-inflammatory activity in ex vivo human blood models, and yet potently
adjuvantic, suggesting that this chemotype may be a safe and effective adjuvant. Our earlier work
on the monoacyl lipopeptide class of TLR2 agonists led to the design of a highly potent lead, but
with negligible aqueous solubility, necessitating the reintroduction of aqueous solubility. We
explored several strategies of introducing ionizable groups on the lipopeptide, as well as the
systematic evaluation of chemically stable bioisosteres of the ester-linked palmitoyl group. These
studies have led to a fully optimized, chemically stable, and highly water-soluble, human TLR2-
specific agonist, which was found to have an excellent safety profile and displayed prominent
adjuvantic activities in rabbit models.
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Introduction
The overall goal of vaccination is the generation of specific, robust, and durable immune
responses against the antigen to provide long-term protection against pathogens. Early
vaccines which frequently utilized killed whole organisms are reactogenic, and are
associated with local and systemic adverse reactions, whole cell pertussis vaccines being an
example.1–4 Modern vaccines such as acellular pertussis vaccines1 use highly purified
antigens. Such ‘subunit vaccines’ have a much more defined composition, facilitating not
only the ease of production and quality control, but importantly, are also considerably less
reactogenic. However, subunit antigens are largely soluble proteins which are intrinsically
poorly immunogenic, and do not induce long-lived immune responses. The recent
reemergence of pertussis in the United States5–7 has served to highlight the rapid waning of
protective immunity following vaccination with acellular subunit pertussis vaccines,8,9 and
emphasizes the need for safe and effective adjuvants.
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Adjuvants initiate early innate immune responses which subsequently lead to the induction
of robust and long-lasting adaptive immunity.10 Aluminum salts (primarily phosphate and
hydroxide), discovered by Glenny and coworkers,11 have been the only adjuvants in clinical
use until the recent introduction of 3-O-desacyl-4′-monophosphoryl lipid A (MPL).12
Aluminum salts (used as adjuvants in acellular pertussis vaccines) are weak adjuvants for
antibody induction, promoting a T helper 2 (Th2)-skewed, rather than a Th1 response,13,14
and are virtually ineffective at inducing cytotoxic T lymphocyte or mucosal IgA antibody
responses. They also appear to promote the induction of IgE isotype switching which has
been associated with allergic reactions in some subjects.13,14
Our knowledge of the molecular mechanisms of innate immunity has expanded rapidly since
the discovery of Toll-like receptors (TLRs)15–17 and of their role in induction and
amplification of adaptive immune responses.18,19 Innate immune afferent signals activated
by vaccine adjuvants include those originating from Toll-like receptors (TLRs), as well as
RIG-I-like receptors20 and NOD-like receptors (NLRs).21,22 There are 10 functional TLRs
encoded in the human genome, which are trans-membrane proteins with an extracellular
domain having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1
receptor (TIR) domain.23 The ligands for these receptors are highly conserved molecules
such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in
combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and
TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9),
and profilin present on uropathogenic bacteria (TLR11).24 TLR1, -2, -4, -5, and -6 recognize
extracellular stimuli, while TLR3, -7, -8 and -9 function within the endolysosomal
compartment.23 The engagement of TLRs by their cognate ligands lead to the production of
inflammatory cytokines, and up-regulation of major histocompatibility complex (MHC)
molecules and co-stimulatory signals in antigen-presenting cells as well as activating natural
killer (NK) cells (innate immune response). These responses result in the priming and
amplification of T-, and B-cell effector functions (adaptive immune responses).25–28
We have been systematically exploring detailed structure-activity relationships (SAR) of
several immunostimulatory TLR agonists,29–37 with a particular focus on TLR2 agonists.
Unlike other TLR-active compounds, agonists of TLR2, first identified in a mycoplasmal
lipopeptide, S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-R-cysteinyl-GNNDESNISFKEK, termed
Macrophage-Activating Lipopeptide-2 1 (MALP-2)38–40 (Fig. 1) and exemplified by the S-
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine 2 (PAM2CS) chemotype30,36 are
of particular interest to us, for although the lipopeptide is devoid of any detectable pro-
inflammatory activity in ex vivo human blood models (as defined by the production of
detectable levels of TNF-α, IL-1β, IL-6, or IL-8),41 or of local reactogenicity and
pyrogenicity in rabbit models,31 it is potently adjuvantic in murine models of
immunization,41 suggesting that this chemotype may be a safe and effective adjuvant.
The exposure of bone marrow-derived dendritic cells of C57/BL6 mice to TLR2-agonistic
lipopeptides results in an upregulation of MHC Class II and CD80/CD86 costimulatory
molecules, with enhanced expression of CD11b and CD11c, associated with the production
of TNF-α and IL-12.42 These results have been confirmed in BALB/c mice using 1, and
extended to show that the lipopeptide also upregulates immunoproteasome (LMP2, LMP7
and MECL1) activity in a dose-dependent manner, suggesting that TLR2 agonists may
indirectly enhance MHC Class I-restricted responses by accelerated antigen processing and
peptide presentation.43 In a recent report comparing the adjuvanticity of several ligands of
TLRs in Chlamydia major outer membrane protein vaccine constructs, TLR2 agonists were
found to be superior in inducing protective responses against a challenge of Chlamydia
trachomatis.44
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Importantly, the effects of lipopeptides on APC maturation and antigen presentation have
also been demonstrated in human dendritic cells (DCs).45 Plasmacytoid and myeloid
dendritic cells (pDCs and mDCs, respectively) constitute the most potent professional
antigen presenting cells, and play a pivotal role in the induction and polarization of antigen-
specific immune responses.46 Human myeloid dendritic cells comprise of two major subsets:
CD1c+ mDCs and CD141+ mDCs, both of which express TLR2.47,48 Furthermore, TLR2
agonists induce isotypic switching and differentiation of naïve human B lymphocytes to
IgG-secreting plasma cells,49 indicating a functional association between BCR stimulation
and TLR activation.49
It is pertinent to highlight anecdotal human data on TLR2 agonists in the context of
tolerability and safety of these compounds. In one study, ten patients with incompletely
resectable pancreas carcinomas were injected intra-tumorally during surgery with 20–30 μg
of 1 followed by postoperative chemotherapy. As expected, the investigators observed influx
of lymphocytes and monocytes in wound secretions, but no systemic side effects were noted.
The study concluded that “up to 20 μg of 1 was well tolerated”.50 In another study, 0.125–
1.0 μg of 1 was directly applied on punch biopsy lesions of the skin in twelve patients; other
than transient and self-limited erythema, no systemic side effects were noted.51 The lack of
proinflammatory activity, excellent safety profile in animal models and human subjects, the
expression of the TLR2 in multiple DC subsets, and its strong adjuvantic activity have been
compelling reasons for our focus on agonists of TLR2.
Our SAR studies on the 2 series of compounds36 led to a simplified second-generation
monoacyl lipopeptide 3 (Fig. 1), in which the spacing between the ester-linked acyl group
and the thioether was found to play a crucial role in determining activity;30 further SAR
studies led to the identification of a cysteine N-acetyl analogue 4, which retained exquisite
human TLR2 (hTLR2)-specificity, with a substantial gain in potency, rivaling that of 2.52
Although highly potent and hTLR2-specific, the acetylation of the cysteine amine in 4 led to
loss of the lone ionizable group and, consequently, to the complete loss of aqueous
solubility. An important component of our work on vaccine adjuvant design and
development has been to engineer complete water solubility into our candidate adjuvants so
as to obviate the need for any excipients, and it therefore became necessary to reintroduce
aqueous solubility in 4. Drawing from our previous SAR studies that the sidechain of the
terminal amino acid (Ser) of the dipeptide unit was not a key determinant of TLR2
activity,30,36,52 an obvious and straightforward approach was to replace it with lysine, the ε-
amine of which was anticipated to restore solubility to the lipopeptide. However, we
observed hydrolytic lability in the analogue, with consequent deterioration of activity. This
observation prompted us to explore various strategies of introducing ionizable groups on the
lipopeptide, as well as the systematic evaluation of stable bioisosteres of the ester-linked
palmitoyl group. Analogues with the serine hydroxyl functionality of the lipopeptide
esterified with L-lysine, succinic acid or nicotinic acid retained hTLR2-specific agonistic
activity, but progressively hydrolyzed to 4 upon prolonged storage, indicating that ester
groups were contributing to lability. These initial observations prompted us to first explore
replacing the ester-linked palmitoyl group with amide, triazole, and carbamate linked long-
chain alkyl groups. A carbamate derivative was found to be more potent than the parent
compound. Aqueous solubility in this analogue was restored by appending a N1,N1-
dimethylpropane-1,3-diamine moiety to the carboxyl group of serine via an amide linkage,
culminating in a fully optimized, stable, and highly water-soluble, human TLR2-specific
agonist with very high potency. The optimized lead compound was found to have an
excellent safety profile in rabbit models, and displayed prominent adjuvantic activities.
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To restore water solubility to 4, we synthesized an analogue with the terminal serine methyl
ester replaced with a lysine methyl ester (Compound 10, Scheme 1). While the lysine
analogue 10 was indeed as active as 4 (EC50 = 1.50 nM, Table 1, 10Fig. 2) and highly water
soluble, we noticed significant loss of activity of aqueous stocks in less than a week. Mass
spectrometry revealed hydrolysis of the methyl ester, presumably via an intramolecular
attack of the ε-amine of lysine, which presaged inadequate shelf-life of vaccine constructs
incorporating as a candidate adjuvant. We next explored analogues with the serine hydroxyl
functionality of 4 esterified with L-lysine (12), sulfated (13), converted to the hemisuccinate
(14) or esterified with nicotinic acid (15) (Scheme 2). All the compounds retained hTLR2-
specific agonistic activity (Table 1, 12Fig. 2), and the lysine conjugate (EC50 = 1.50 nM),
the sulfate 13 (EC50 = 5.84 nM), as well as hemisuccinate 14 (EC50 = 0.65 nM) were found
to be highly water soluble. As observed for compound 10, aqueous stocks of compound 12
were also found to be unstable, and a white precipitate of its parent compound 4 was
observed (confirmed by TLC and LC-MS) upon prolonged storage, indicating that
compound 12 was behaving as a water-soluble, but relatively unstable prodrug of compound
4.
Given that the mono-acyl lipopeptides are human TLR2-specific, murine models of
immunization that we had used previously34 to benchmark adjuvantic activity were
inappropriate, and it was of importance to verify whether the rabbit model34,53 that we had
subsequently adopted as a screen would be suitable to evaluate the adjuvanticity of this
chemotype. We elected first to evaluate the adjuvanticity of the highly water-soluble 12
using bovine α-lactalbumin as a model subunit antigen34,53 and under excipient-free
conditions, reasoning that degradation in vivo of 12 would yield 4, which would retain
TLR2-agonistic activity. We were gratified to find that the water soluble monoacyl
lipopeptide 12 showed excellent induction of anti-bovine α-lactalbumin IgG responses in
rabbits using a prime+dual-boost model (Fig. 3), validating the relevance of the animal
model, and demonstrating excellent adjuvanticity.
Having observed lability of two ester groups, both of which undermine and compromise the
activity and shelf-life, we set out to design out all of the labile groups in our lead compound
4, beginning with the replacement of the ester-linked palmitoyl group with amide-
(compound 22, Scheme 3), triazole- (compounds 24 and 27, Scheme 4) and carbamate-
(compounds 31 and 34, Scheme 5) linked long-chain alkyl groups.
Starting from L-cystine, the advanced intermediate 18 was synthesized as reported by us
earlier.30,52 The hydroxyl functionality in 18 was mesylated and displaced by sodium azide
to furnish the azido compound 19 (73% over two steps, Scheme 3). A Staudinger azide
reduction protocol was used for the synthesis of amino compound 20, which was N-
palmitoylated to obtain 21. Global deprotection and controlled acetylation (yielding
predominantly the cystine N-acetylated product) furnished the desired amide-linked
derivative 22. The triazole linked derivatives 24 and 27 were designed based on the fact that
substituted 1,2,3-triazoles are popular functionalities used in drug discovery for the
bioisosteric replacement of key functional groups. They are also known to readily associate
with biological targets through hydrogen-bonding and dipole interactions.54,55 The azido
intermediate 19 described above was a convenient synthon for the copper(I)-catalyzed
Huisgen 1,3-dipolar cycloaddition reaction for the synthesis of the 4-alkyl-1H-1,2,3-
triazol-1-yl compound 24. Pentadec-1-yne was selected as an alkyne component in this
reaction to maintain the overall length of the molecule. The regioisomeric 1-alkyl-1H-1,2,3-
triazol-4-yl analogue 27 was also synthesized by swapping the alkyne and azide
functionalities in the respective synthons (Scheme 4); the alkyne component 25 was
Salunke et al. Page 4













synthesized by alkylation of mercapto-dipeptide 17 with 4-bromobut-1-yne, while 1-
azidohexadecane was synthesized from 1-bromohexadecane using sodium azide in DMF.
The synthesis of the carbamate-linked analogue 29 was achieved by treatment of the primary
alcohol functionality in compound 18 with 1,1′-carbonyldiimidazole (CDI) in
dichloromethane (DCM), and reacting in situ the imidazolecarboxylate intermediate 28 with
hexadecylamine (Scheme 5). The desired derivative 31 was synthesized as reported for the
synthesis of compound 22. The regioisomeric carbamate derivative 34 was synthesized
simply by the reaction of 20 with cetylchloroformate and further elaboration as reported for
compounds 22 or 31.
The triazole derivatives 24 (EC50 = 0.29 μM, Table 1, 27Fig. 4) and (EC50 = 1.02 μM, Table
1, 22Fig. 4) were found to be the least active in TLR2 agonism assay. The loss in activity
was also observed in amide derivative (EC50 = 12.78 nM, Table 1, 31Fig. 4). We were
delighted to observe in our cell-based reporter gene assays that the carbamate derivative was
as potent (EC50 = 0.32 nM, Table 1, 4Fig. 4) as , and its regioisomer 34 was highly active
(34: EC50 = 65 pM; 4: EC50 = 0.66 nM; Table 1, Fig. 4).
Aqueous solubility in the highly potent and stable carbamate derivative 34 was restored by
appending a N1,N1-dimethylpropane-1,3-diamine moiety to the carboxyl group of serine via
a stable amide linkage (compound 38, Scheme 6), an approach that is similar to attaching a
polar polyethylene glycol unit to the terminal amino acid residue.56 Our initial attempts at
hydrolyzing the methyl ester in compound 32 for coupling the N1,N1-dimethylpropane-1,3-
diamine using conventional lithium hydroxide protocols resulted in epimerization of the
stereocenters, yielding the target compound in its racemic form (EC50 = 1.29 nM). We
successfully utilized the mild and selective trimethytin hydroxide ester hydrolysis method
developed by Nicolaou57 and obtained compound 35 in enantiopure form. Subsequent
amidation of 35 using N1,N1-dimethylpropane-1,3-diamine and further elaboration resulted
in the highly water soluble (>10 mg/mL) and highly potent (EC50 = 0.25 nM, Table 1)
enantiopure final compound 38, which retained excellent chemical stability under
accelerated stability testing conditions.
The combination of highly desired attributes of high potency (in primary screens), excellent
aqueous solubility, and chemical stability in 38 warranted a careful evaluation of this
compound in secondary screens. Consistent with our earlier findings that 2 induced virtually
undetectable levels of proinflammatory mediators such as TNF-α, IL-1β and IL-18,31 we
could not detect any significant proinflammatory cytokine signatures in human PBMCs or
human whole blood stimulated with 38 using our standard 5-plex cytometric bead
assays35,41 (data not shown). In an effort to understand in greater detail the basis of the
potent adjuvanticity of TLR2 agonists that appears to be entirely dissociated from the
induction of proinflammatory cytokines, we examined 38 in a 41-plex immunoassay that we
have recently implemented. We observed prominent biphasic induction of the chemokines
monocyte chemotactic protein-1 (MCP-1), and MCP-3, macrophage-derived chemokine
(MDC), as well as interleukin-8 (IL-8, also a chemokine; Fig. 6). The rather unexpected
finding of strong macrophage-derived or -targeted chemokine induction prompted us to
examine markers of monocytic activation in ex vivo flow cytometric assays using whole
human blood. As previously reported,31 TLR2 and TLR4 agonists induce CD11b
upregulation in human granulocytes, and we found that 38 indeed upregulated CD11b very
potently, relative to 2 (Fig. 6, left panel) in neutrophils; however, we also observed strong
monocytic CD11b upregulation (Fig. 6, right panel), which has not been previously reported
for agonists of TLR2. Although we cannot as yet establish a causal relationship between
monocytic activation and chemokine production on the one hand, and adjuvanticity on the
other, these biomarkers will likely prove useful in evaluating several other chemotypes
which we are currently examining.
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Cautious of the very high potency of 38, we elected to first evaluate the safety of this
lipopeptide in rabbit models. A dose-escalation study in rabbits up to 100 μg/animal
(administered intramuscularly, or as an intravenous bolus) did not result in any observable
adverse effects. Whereas a dose of 1 μg of LPS evoked prominent leucopenia,
lymphocytopenia (Fig. 7a–b) and febrile responses (Fig. 7c) in the animals, 100 μg of 38 did
not induce any such effects (Fig. 7).
Encouraged by the excellent safety profile, we proceeded to evaluate the adjuvanticity of 38.
Non-alum-adsorbed, toxoided pertussis antigens are not commercially available, and we
therefore chose CRM197, a nontoxic mutant of diphtheria toxin as a test-antigen.58 The
excellent solubility of the lipopeptide allowed excipient-free formulation of the test-antigen
and adjuvant in sterile saline. Pre-immune test-bleeds were first obtained via venipuncture of
the marginal vein of the ear. Rabbits were then immunized intramuscularly on Days 1, 15,
and 28 with antigen-sparing doses (10 μg/dose) of unadjuvanted CRM197 in saline, or
adjuvanted with 100 μg/dose of 38 in a total volume of 0.2 mL. A test bleed was performed
on Day 25 (ten days after the first boost) and a final bleed was performed via the marginal
vein of the ear on Day 38. Sera were stored at −80 °C until used. CRM197-specific IgG
titers in sera were quantified by conventional antibody-capture ELISA techniques performed
in 384-well format using automated liquid handling methods as described by us.34,53 We
were gratified to find rapid and robust anti-CRM197 IgG titers in animals receiving the
adjuvant (Fig. 8), as compared to unadjuvanted controls.
We have been fortunate in being able to successfully apply principles of classical medicinal
chemistry and rational drug optimization to an unexpected problem of chemical stability,
achieving in the process augmented potency, excellent aqueous solubility and, importantly,
preserving safety and efficacy. The identification of key chemokine biomarkers for TLR2




All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed
to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 μm
analytical reverse phase C18 column with H2Oisopropanol or H2O-CH3CN gradients and an
Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the positive ion
(or negative ion, as appropriate) acquisition mode.
Synthesis of Compound 6: (2S,2′S)-Dimethyl 2,2′-(((2R,2′R)-3,3′-
disulfanediylbis(2-acetamidopropanoyl))bis(azanediyl))bis(6-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino) hexanoate)—To a solution of L-cystine (500 mg, 2.08
mmol) in water (10 mL) were added triethylamine (870 μL, 6.24 mmol) and di-tert-
butyldicarbonate (1.35 g, 6.24 mmol). The reaction mixture was stirred at room temperature
for 2 h. After completion of the reaction, the solvent was evaporated under reduced pressure.
The residue was dissolved in ethyl acetate and washed with 10% HCl. The organic layer was
dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to
obtain the crude product which was purified using column chromatography (15% MeOH/
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CH2Cl2) to obtain compound Nα,Nα′-di-Boc-L-cystine (870 mg, 95%). To a solution of
Nα,Nα′-di-Boc-L-cystine (500 mg, 1.13 mmol) in anhydrous DMF (15 mL) were added H-
Lys( Fmoc)-OMe·HCl (1.05 g, 2.50 mmol), HOBt (338 mg, 2.50 mmol), and pyridine (411
μL, 4.50 mmol). The reaction mixture was stirred at 0 °C for 30 min, followed by addition
of EDCI (958 mg, 5.00 mmol) at 0 °C. The reaction mixture was stirred at room temperature
for 16 h, followed by evaporation of the solvent under reduced pressure. The residue was
then dissolved in ethyl acetate and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to obtain the
crude product which was purified using column chromatography (50% EtOAc/hexanes) to
obtain compound 5 (1.10 g, 83%). MS (ESI-TOF) for C60H76N6O14S2 [M+H]+ Found
1169.5011, Calculated 1169.4934; [M+Na]+ Found 1191.4834, Calculated 1191.4753.
Compound 5 (600 mg, 0.51 mmol) was dissolved in hydrogen chloride solution (10 mL, 4M
in dioxane) and the reaction mixture was stirred at room temperature for an hour and the
volatilities were removed to afford (2S,2′S)-dimethyl 2,2′-(((2R,2′R)-3,3′-
disulfanediylbis(2-aminopropanoyl))bis(azanediyl))bis(6-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)hexanoate) dihydrochloride salt (535 mg, 0.51 mmol). The
crude product was dissolved in CH2Cl2 (5 mL) and pyridine (5 mL). Acetic anhydride (291
μL, 3.08 mmol) was added and the reaction mixture was stirred at room temperature for 2h,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in ethyl acetate and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to obtain the
crude product which was purified using column chromatography (50% EtOAc/hexanes) to
obtain compound 6 (425 mg, 79% over two steps). 1H NMR (500 MHz, CDCl3) δ 8.46 (d, J
= 7.1 Hz, 2H), 7.74 (d, J = 7.5 Hz, 4H), 7.57 (d, J = 7.4 Hz, 4H), 7.38 (t, J = 7.4 Hz, 4H),
7.29 (t, J = 7.5 Hz, 4H), 6.72 (d, J = 9.1 Hz, 2H), 5.45 (td, J = 9.9, 3.2 Hz, 2H), 4.94 (t, J =
5.4 Hz, 2H), 4.48 – 4.32 (m, 6H), 4.18 (t, J = 6.8 Hz, 2H), 3.71 (s, 6H), 3.20 – 3.03 (m, 6H),
2.94 – 2.83 (m, 2H), 2.02 (s, 6H), 1.91 – 1.68 (m, 4H), 1.58 – 1.31 (m, 8H). 13C NMR (126
MHz, CDCl3) δ 172.4, 170.7, 156.5, 144.1, 141.4, 127.8, 127.2, 125.1, 120.1, 66.6, 53.2,
52.7, 52.5, 47.4, 46.2, 40.8, 31.2, 29.5, 23.5, 22.8. MS (ESI-TOF) for C54H64N6O12S2 [M
+H]+ Found 1053.4234, Calculated 1053.4096; [M+Na]+ Found 1075.4048, Calculated
1075.3916.
Synthesis of Compound 9: (9S,12R)-12-Acetamido-1-(9H-fluoren-9-yl)-9-
(methoxycarbonyl)-3,11-dioxo-2-oxa-14-thia-4,10-diazahexadecan-16-yl
palmitate—To a solution of 6 (375 mg, 0.356 mmol) in CH2Cl2 (5 mL) were added water
(100 μL) and tributylphosphine (356 μL, 1.43 mmol). The reaction mixture was stirred at
room temperature for 2 h. After completion of the reaction, the solvent was removed under
reduced pressure to obtain the crude product, which was purified using column
chromatography (50% EtOAc/hexanes) to obtain compound 7 (250 mg, 66%). MS (ESI-
TOF) for C27H33N3O6S [M+H]+ Found 528.2232, Calculated 528.2163; [M+Na]+ Found
550.2061, Calculated 550.1988. To a solution of compound 7 (245 mg, 0.465 mmol) in
DMF (5 mL) were added 2-iodoethanol (182 μL, 2.33 mmol) and potassium carbonate (320
mg, 2.33 mmol). The reaction mixture was stirred at room temperature for an hour. After
completion of the reaction, the solid potassium carbonate was filtered out and the solvent
was removed under reduced pressure to obtain the crude product, which was purified using
column chromatography (5% MeOH/CH2Cl2) to obtain compound 8 as a white solid (111
mg, 42%). MS (ESI-TOF) for C29H37N3O7S [M+H]+ Found 572.2427, Calculated
572.2425; [M+Na]+ Found 594.2255, Calculated 594.2244. Compound 8 (100 mg, 0.175
mmol) was then dissolved in CH2Cl2 (1 mL) and pyridine (1 mL). Palmitoyl chloride (80
μL, 0.262 mmol) was added and the reaction mixture was stirred at room temperature for 1
h. After completion of the reaction, the solvents were removed under reduced pressure to
obtain the crude product, which was purified using column chromatography (50% EtOAc/
Salunke et al. Page 7













hexanes) to obtain compound 9 (133 mg, 94%). 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J =
7.5 Hz, 2H), 7.60 (d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.07
(d, J = 7.7 Hz, 1H), 6.54 (d, J = 7.2 Hz, 1H), 5.12 (t, J = 5.7 Hz, 1H), 4.63 – 4.50 (m, 2H),
4.46 – 4.35 (m, 2H), 4.31 – 4.16 (m, 3H), 3.73 (s, 3H), 3.17 (td, J = 13.6, 6.9 Hz, 2H), 2.92
(qd, J = 14.0, 6.4 Hz, 2H), 2.82 (td, J = 6.6, 1.9 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 2.01 (s,
3H), 1.89 (ddd, J = 14.9, 10.8, 5.7 Hz, 1H), 1.79 – 1.66 (m, 1H), 1.65 – 1.56 (m, 2H), 1.56 –
1.47 (m, 2H), 1.45 – 1.33 (m, 2H), 1.33 – 1.21 (m, 24H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 174.05, 172.33, 170.53, 170.38, 156.76, 144.11, 144.08, 141.44,
127.81, 127.17, 125.17, 120.11, 66.67, 62.76, 52.68, 52.64, 52.39, 47.39, 40.53, 34.34,
34.26, 32.06, 31.64, 31.15, 29.83, 29.79, 29.76, 29.62, 29.50, 29.42, 29.36, 29.28, 25.02,
23.20, 22.83, 22.40, 14.27. MS (ESI-TOF) for C45H67N3O8S [M+H]+ Found 810.4754,
Calculated 810.4722; [M+Na]+ Found 832.4591, Calculated 832.4541.
Synthesis of Compound 10: 2-(((R)-2-Acetamido-3-(((S)-6-amino-1-methoxy-1-
oxohexan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a solution of
compound 9 (81 mg, 0.1 mmol) in DMF (1 mL) was added polymer-bound piperazine (1–2
mmol/g loading) (333 mg, ~ 0.5 mmol) and the reaction mixture was stirred at room
temperature for 4 h. After completion of the reaction, the resin was filtered out and the
solvents were removed under reduced pressure to obtain the crude product, which was
purified using column chromatography (20% MeOH/CH2Cl2) to obtain compound 10 as a
white solid (32 mg, 55%). 1H NMR (500 MHz, CDCl3) δ 8.03 (d, J = 7.9 Hz, 1H), 7.05 (d, J
= 8.4 Hz, 1H), 4.84 (td, J = 8.0, 5.5 Hz, 1H), 4.54 (dd, J = 13.8, 7.4 Hz, 1H), 4.31 – 4.15 (m,
2H), 3.73 (s, 3H), 3.06 (ddd, J = 19.2, 13.6, 6.2 Hz, 3H), 2.92 – 2.72 (m, 3H), 2.34 – 2.26
(m, 2H), 2.06 (s, 3H), 1.97 – 1.88 (m, 1H), 1.85 (dd, J = 15.0, 7.7 Hz, 2H), 1.77 – 1.67 (m,
1H), 1.59 (dd, J = 14.3, 7.2 Hz, 4H), 1.40 – 1.17 (m, 24H), 0.87 (t, J = 7.0 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 174.01, 172.17, 171.42, 170.90, 63.08, 52.63, 52.40, 39.05,
34.97, 34.36, 32.07, 31.19, 30.21, 29.85, 29.82, 29.81, 29.79, 29.66, 29.51, 29.46, 29.33,
26.58, 25.06, 23.41, 22.84, 22.07, 14.28. MS (ESI-TOF) for C30H57N3O6S [M+H]+ Found
588.4086, Calculated 588.4041; [M+Na]+ Found 610.3914, Calculated 610.3860.
Synthesis of 12: 2-(((R)-2-Acetamido-3-(((S)-3-(((S)-2,6-
diaminohexanoyl)oxy)-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl palmitate—To a solution of N,N′-di-boc-L-lysine (63 mg, 0.183
mmol) and compound 4 (50 mg, 0.091 mmol) in anhydrous CH2Cl2 (5 mL), were added N-
methylmorpholine (20 μL, 0.183 mmol) and catalytic amount of DMAP. The reaction
mixture was stirred at 0 °C and EDCI (28 mg, 0.183 mmol) was added after 15 min. The
reaction mixture was then stirred at room temperature for 4 h. After the completion of
reaction, water (10 mL) was added and the product was extracted in CH2Cl2. The organic
layer was washed with water (10 mL × 2), brine (10 mL) and dried over anhydrous sodium
sulfate. The solvent was removed under vacuum and the residue was purified using column
chromatography (5 % MeOH/CH2Cl2) to obtain the diboc protected intermediate 11 as
white solid (40 mg, 50%). 1H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 7.6 Hz, 1H), 6.74 (d, J
= 7.6 Hz, 1H), 5.23 (d, J = 6.6 Hz, 1H), 4.83 (dt, J = 7.7, 3.9 Hz, 1H), 4.77 (s, 1H), 4.66 (d,
J = 6.3 Hz, 1H), 4.58 (d, J = 10.0 Hz, 1H), 4.45 (dd, J = 11.2, 3.9 Hz, 1H), 4.32 – 4.14 (m,
3H), 3.78 (s, 3H), 3.18 – 3.07 (m, 2H), 2.97 (qd, J = 13.9, 6.4 Hz, 2H), 2.85 – 2.74 (m, 2H),
2.31 (t, J = 7.6 Hz, 2H), 2.07 (s, 3H), 1.86 – 1.55 (m, 6H), 1.55 – 1.41 (m, 18H), 1.41 – 1.20
(m, 24H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.95, 172.59, 170.84,
170.57, 169.19, 156.49, 155.86, 80.25, 79.42, 63.83, 62.93, 53.54, 53.15, 52.66, 52.15,
39.84, 34.35, 33.95, 32.07, 31.67, 31.11, 29.84, 29.80, 29.77, 29.63, 29.51, 29.44, 29.30,
28.59, 28.50, 25.04, 23.25, 22.84, 22.48, 14.28. MS (ESI-TOF) for C43H78N4O12S [M+H]+
Found 875.5417, Calculated 875.5410; [M+Na]+ Found 897.5232, Calculated 897.5229.
Compound 11 was then dissolved in HCl/dioxane (4 M solution, 2 mL) and the reaction
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mixture was stirred at room temperature for 15 min, followed by removal of the solvent
under vacuum to obtain compound 12 as a white solid in quantitative yield. 1H NMR (500
MHz, DMSO) δ 8.80 (d, J = 8.1 Hz, 1H), 8.63 (s, 3H), 8.31 (d, J = 8.3 Hz, 1H), 7.95 (s, 3H),
4.72 (ddd, J = 7.9, 6.3, 4.9 Hz, 1H), 4.46 (ddd, J = 15.7, 10.0, 4.7 Hz, 2H), 4.38 (dd, J =
11.2, 6.4 Hz, 1H), 4.18 – 4.11 (m, 2H), 3.97 (bs, 1H), 3.73 – 3.69 (m, 1H), 3.69 – 3.64 (m,
4H), 3.52 – 3.48 (m, 1H), 3.46 (ddd, J = 6.1, 3.9, 1.2 Hz, 1H), 2.93 (dd, J = 13.7, 4.8 Hz,
1H), 2.83 – 2.72 (m, 4H), 2.67 (dd, J = 13.7, 9.4 Hz, 1H), 2.28 (t, J = 7.4 Hz, 2H), 1.88 (s,
3H), 1.84 – 1.77 (m, 2H), 1.62 – 1.32 (m, 8H), 1.30 – 1.18 (m, 24H), 0.85 (t, J = 6.9 Hz,
3H). 13C NMR (126 MHz, DMSO) δ 172.81, 170.76, 169.68, 169.23, 168.91, 72.17, 70.53,
63.95, 62.88, 60.18, 52.44, 51.67, 50.78, 43.63, 38.23, 33.53, 33.41, 31.31, 30.01, 29.11,
29.06, 29.03, 29.02, 29.00, 28.90, 28.72, 28.46, 26.19, 24.44, 22.55, 22.12, 21.13, 13.99. MS
(ESI-TOF) for C33H62N4O8S [M+H]+ Found 675.4181, Calculated 675.4361.
Synthesis of 13: 2-(((R)-2-Acetamido-3-(((S)-1-methoxy-1-oxo-3-
(sulfooxy)propan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a solution of
compound 4 (60 mg, 0.110 mmol) in anhydrous pyridine was added sulfur trioxide pyridine
complex (175 mg, 1.10 mmol). The reaction mixture was heated at 80 °C for 16 h. The
solvent was removed under reduced pressure to obtain the residue which was purified using
column chromatography (10% MeOH/CH2Cl2), to furnish compound 13 as a white solid (23
mg, 33%). 1H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 5.3 Hz, 1H), 7.30 (d, J = 1.6 Hz, 1H),
4.92 – 4.79 (m, 2H), 4.32 (dd, J = 33.8, 6.7 Hz, 2H), 4.26 – 4.14 (m, 2H), 3.76 (s, 3H), 3.00
(d, J = 9.1 Hz, 1H), 2.89 (dd, J = 12.8, 6.8 Hz, 1H), 2.78 (t, J = 6.4 Hz, 2H), 2.36 – 2.26 (m,
3H), 2.02 (s, 3H), 1.59 (dd, J = 14.3, 7.2 Hz, 2H), 1.35 – 1.22 (m, 24H), 0.88 (t, J = 7.0 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 174.00, 172.28, 171.43, 170.29, 67.45, 62.92, 53.15,
52.60, 52.19, 34.36, 32.08, 30.97, 29.87, 29.86, 29.82, 29.71, 29.52, 29.51, 29.38, 25.08,
23.01, 22.85, 14.28. MS (ESI-TOF, Negative Mode) for C27H50N2O10S2, [M−H]− Found
625.2633, Calculated 625.2834.
Synthesis of 14: (7S,10R)-10-Acetamido-7-(methoxycarbonyl)-4,9,16-
trioxo-5,15-dioxa-12-thia-8-azahentriacontan-1-oic acid—To a solution of
compound 4 (50 mg, 0.091 mmol) in anhydrous THF were added triethylamine (25 μL,
0.183 mmol) and succinic anhydride (18 mg, 0.183 mmol). The reaction mixture was stirred
at 50 °C for 2 h. The solvent was removed under vacuum to obtain the residue which was
purified using column chromatography (10% MeOH/CH2Cl2), to furnish compound 14 (37
mg, 62%). 1H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 7.8 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H),
4.87 – 4.78 (m, 2H), 4.65 (dd, J = 11.4, 3.5 Hz, 1H), 4.39 (dd, J = 11.4, 3.4 Hz, 1H), 4.34 –
4.19 (m, 2H), 3.79 (s, 3H), 2.99 (dd, J = 14.0, 5.9 Hz, 1H), 2.87 (dd, J = 14.0, 7.2 Hz, 1H),
2.81 (td, J = 6.8, 1.0 Hz, 2H), 2.75 – 2.53 (m, 4H), 2.37 – 2.29 (m, 2H), 2.08 (s, 3H), 1.66 –
1.56 (m, 2H), 1.35 – 1.21 (m, 24H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
175.28, 174.54, 171.84, 171.65, 170.25, 169.41, 63.29, 63.04, 53.10, 52.40, 52.03, 34.58,
34.39, 32.06, 30.90, 29.84, 29.80, 29.76, 29.67, 29.61, 29.50, 29.41, 29.39, 29.27, 25.00,
23.36, 22.83, 14.27. MS (ESI-TOF) for C31H54N2O10S [M+H]+ Found 647.3649,
Calculated 647.3572; [M+Na]+ Found 669.3476, Calculated 669.3391.
Synthesis of 15: (S)-2-((R)-2-Acetamido-3-((2-
(palmitoyloxy)ethyl)thio)propanamido)-3-methoxy-3-oxopropyl nicotinate—To
a solution of compound 4 (50 mg, 0.091 mmol) and nicotinic acid (23 mg, 0.183 mmol) in
anhydrous CH2Cl2 (5 mL), were added N-methylmorpholine (20 μL, 0.183 mmol) and
catalytic amount of DMAP. The reaction mixture was stirred at 0 °C and EDCI (28 mg,
0.183 mmol) was added after 15 min. The reaction mixture was then stirred at room
temperature overnight. After completion of the reaction, water (10 mL) was added and the
product was extracted in CH2Cl2. The organic layer was washed with water (10 mL × 2),
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brine (10 mL) and dried over anhydrous sodium sulfate. The solvent was removed under
vacuum and the residue was purified using column chromatography (5 % MeOH/CH2Cl2) to
obtain product 15 as a white solid (41 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 9.19 (dd, J
= 2.2, 0.8 Hz, 1H), 8.80 (dd, J = 4.9, 1.7 Hz, 1H), 8.30 – 8.23 (m, 1H), 7.48 (d, J = 7.6 Hz,
1H), 7.41 (ddd, J = 8.0, 4.9, 0.8 Hz, 1H), 6.44 (d, J = 7.1 Hz, 1H), 4.95 (dt, J = 7.7, 3.8 Hz,
1H), 4.77 – 4.65 (m, 2H), 4.61 (td, J = 7.2, 5.7 Hz, 1H), 4.32 – 4.18 (m, 2H), 3.82 (s, 3H),
2.99 (dd, J = 14.0, 5.6 Hz, 1H), 2.93 – 2.75 (m, 3H), 2.34 – 2.24 (m, 2H), 2.01 (s, 3H), 1.62
(s, 3H), 1.62 – 1.53 (m, 2H), 1.36 – 1.18 (m, 24H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 174.05, 170.51, 170.44, 169.36, 164.88, 154.04, 151.18, 137.36, 125.39,
123.56, 64.41, 62.61, 53.28, 52.55, 52.23, 34.35, 33.99, 32.07, 31.20, 29.84, 29.80, 29.77,
29.62, 29.51, 29.42, 29.29, 25.02, 23.21, 22.84, 14.28. MS (ESI-TOF) for C33H53N3O8S [M
+H]+ Found 652.3672, Calculated 652.3626; [M+Na]+ Found 674.3472, Calculated
674.3446.
Synthesis of 19: (S)-Methyl 2-((R)-3-((2-azidoethyl)thio)-2-((tert-
butoxycarbonyl)amino) propanamido)-3-(tert-butoxy)propanoate—To a solution
of compound 18 (500 mg, 1.185 mmol) in CH2Cl2 (5 mL) were added triethylamine (0.5
mL, 3.56 mmol) and methanesulfonyl chloride (276 μL, 3.55 mmol) and the reaction
mixture was stirred at room temperature for 3 h. After the completion of the reaction, water
(10 mL) was added and the product was extracted in CH2Cl2. The organic layer was washed
with water (10 mL × 2) and brine (10 mL), dried over anhydrous sodium sulfate and the
solvent was removed under reduced pressure to obtain the crude mesylate. This crude
product was dissolved in DMF (5 mL) and sodium azide (385 mg, 5.925 mmol) was added
and the reaction mixture was stirred at 60 C for 4 h. After completion of the reaction, water
(20 mL) was added to the reaction and the product obtained was extracted in EtOAc. The
organic layer was washed with water (10 mL × 3) and brine (10 mL), dried over anhydrous
sodium sulfate and the solvent was removed under reduced pressure to obtain the crude
product which was purified using column chromatography (20% EtOAc/hexanes) to obtain
compound 19 (390 mg, 73% over two steps). 1H NMR (500 MHz, CDCl3) δ 7.14 (d, J = 7.8
Hz, 1H), 5.49 (s, 1H), 4.66 (dt, J = 8.2, 3.0 Hz, 1H), 4.32 (d, J = 4.9 Hz, 1H), 3.83 (dd, J =
9.1, 2.9 Hz, 1H), 3.74 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3.51 (ddd, J = 12.5, 9.0, 6.2
Hz, 2H), 3.02 (dd, J = 14.0, 5.1 Hz, 1H), 2.90 (dd, J = 14.0, 7.0 Hz, 1H), 2.79 (ddd, J = 12.1,
9.5, 3.7 Hz, 2H), 1.46 (s, 9H), 1.14 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.59, 170.41,
155.40, 80.47, 73.70, 61.76, 53.93, 53.31, 52.60, 51.14, 34.89, 31.86, 28.43, 27.41. MS
(ESI-TOF) for C18H33N5O6S [M+Na]+ Found 470.1919, Calculated 470.2044.
Synthesis of 20: (S)-Methyl 2-((R)-3-((2-aminoethyl)thio)-2-((tert-
butoxycarbonyl)amino) propanamido)-3-(tert-butoxy)propanoate—To a solution
of compound 19 (237 mg, 0.53 mmol) in dry THF (5 mL) was added triphenylphosphine
(208 mg, 0.795 mmol) and the reaction mixture was heated to reflux for 3 h. Water (1 mL)
was added and the heating was continued for 2 more hours. After the completion of reaction,
the solvent was removed under reduced pressure to obtain the crude product which was
purified using column chromatography (10% MeOH/CH2Cl2) to obtain compound 19 (200
mg, 90%). 1H NMR (500 MHz, CDCl3) δ 7.57 (bs, 1H), 5.73 (d, J = 7.5 Hz, 1H), 4.74 –
4.61 (m, 1H), 4.35 (bs, 1H), 3.82 (dd, J = 9.1, 3.0 Hz, 1H), 3.73 (s, 3H), 3.57 (dd, J = 9.1,
3.3 Hz, 1H), 3.03 – 2.80 (m, 4H), 2.79 – 2.63 (m, 2H), 1.45 (s, 9H), 1.13 (s, 9H). 13C NMR
(126 MHz, CDCl3) δ 170.7, 170.6, 155.5, 80.3, 73.6, 61.9, 54.0, 53.3, 52.5, 41.4, 36.4, 34.9,
28.5 (3C), 27.4 (3C). MS (ESI-TOF) for C18H35N3O6S [M+H]+ Found 470.1919,
Calculated 470.2044.
Synthesis of 21: (S)-Methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-((2-palmitamidoethyl)thio)propanamido)propanoate
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—To a solution of compound 20 (100 mg, 0.238 mmol) in dry CH2Cl2 (2 mL) were added
triethylamine (50 mL, 0.356 mmol) and palmitoyl chloride (109 mL, 0.356 mmol) and the
reaction mixture was stirred at room temperature for 30 min. After the completion of
reaction, water (10 mL) was added to the reaction and the product obtained was extracted in
CH2Cl2. The organic layer was washed with water (10 mL × 3) and brine (10 mL), dried
over anhydrous sodium sulfate and the solvent was removed under reduced pressure to
obtain the crude product which was purified using column chromatography (40% EtOAc/
hexanes) to obtain compound 21 (105 mg, 69%). 1H NMR (500 MHz, CDCl3) δ 7.14 (d, J =
8.1 Hz, 1H), 6.25 (s, 1H), 5.48 (d, J = 4.1 Hz, 1H), 4.66 (dt, J = 8.2, 3.1 Hz, 1H), 4.32 (d, J
= 5.6 Hz, 1H), 3.83 (dd, J = 9.1, 3.0 Hz, 1H), 3.74 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H),
3.48 (td, J = 9.3, 6.0 Hz, 2H), 2.97 (dd, J = 13.9, 5.5 Hz, 1H), 2.88 (dd, J = 13.9, 6.9 Hz,
1H), 2.82 – 2.66 (m, 2H), 2.24 – 2.13 (m, 2H), 1.67 – 1.56 (m, 2H), 1.45 (s, 9H), 1.37 – 1.19
(m, 24H), 1.14 (s, 9H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.53,
170.71, 170.50, 155.50, 80.47, 73.75, 61.76, 53.88, 53.30, 52.62, 38.58, 36.86, 34.55, 32.51,
32.06, 29.84, 29.80, 29.78, 29.71, 29.67, 29.54, 29.50, 28.45, 27.43, 25.88, 22.83, 14.27. MS
(ESI-TOF) for C34H65N3O7S [M+H]+ Found 660.4560, Calculated 660.4616; [M+Na]+
Found 682.4373, Calculated 682.4435.
Synthesis of 22: (S)-Methyl 2-((R)-2-acetamido-3-((2-
palmitamidoethyl)thio)propanamido)-3-hydroxypropanoate—To compound 21
(95 mg, 0.183 mmol) was added TFA (2 mL). The reaction mixture was stirred at room
temperature for 30 min and then dried by blowing nitrogen through the solution. The crude
product was used directly for the next step. To a solution of the crude intermediate in
CH2Cl2 (2 mL) was added pyridine (16 μL, 0.2 mmol) and acetic anhydride (19 μL, 0.2
mmol). The reaction mixture was stirred at room temperature for 30 min and then
concentrated. The residue was purified by a flash chromatography (5% MeOH/CH2Cl2) to
give product 22 (70 mg, 84%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J =
7.8 Hz, 1H), 6.75 (d, J = 7.3 Hz, 1H), 6.07 (s, 1H), 4.71 (d, J = 7.1 Hz, 1H), 4.62 (dd, J =
7.7, 3.3 Hz, 1H), 4.01 (s, 2H), 3.78 (s, 2H), 3.63 – 3.48 (m, 2H), 2.95 (dd, J = 22.3, 6.2 Hz,
2H), 2.85 (dt, J = 14.2, 5.7 Hz, 1H), 2.72 (dt, J = 14.5, 7.4 Hz, 1H), 2.23 – 2.19 (m, 1H),
2.06 (s, 2H), 1.63 – 1.56 (m, 2H), 1.34 – 1.22 (m, 18H), 0.88 (t, J = 6.9 Hz, 2H). 13C NMR
(126 MHz, CDCl3) δ 175.10, 170.66, 170.61, 170.55, 62.88, 55.43, 52.78, 52.28, 39.22,
37.01, 35.36, 32.75, 32.07, 29.85, 29.84, 29.81, 29.77, 29.63, 29.51, 29.45, 29.40, 25.80,
23.35, 22.84, 14.28. MS (ESI-TOF) for C27H51N3O6S [M+H]+ Found 546.3474, Calculated
546.3571; [M+Na]+ Found 568.3293, Calculated 568.3391.
Synthesis of Compound 23: (S)-methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-((2-(4-tridecyl-1H-1,2,3-triazol-1-
yl)ethyl)thio)propanamido)propanoate—To a stirred solution of compound 19 (60
mg, 0.134 mmol) and pentadec-1-yne (39 μL, 0.147 mmol) in THF (2 mL), were added
CuSO4.5H2O (3 mg in 0.25 mL water, 0.013 mmol) and sodium ascorbate (5 mg in 0.25 mL
water, 0.003 mmol) and the reaction mixture was stirred at room temperature for overnight.
After the completion of reaction, water (10 mL) was added and the product obtained was
extracted in EtOAc. The organic layer was washed with water (10 mL × 2) and brine (10
mL), dried over anhydrous sodium sulfate and the solvent was removed under reduced
pressure to obtain the crude product. The residue was further purified by a flash
chromatography (5% MeOH/CH2Cl2) to give product 23 (48 mg, 55%) as a white solid. 1H
NMR (500 MHz, CDCl3) δ 7.43 (s, 1H), 7.12 (d, J = 7.6 Hz, 1H), 5.51 (d, J = 4.1 Hz, 1H),
4.64 (dt, J = 8.2, 3.1 Hz, 1H), 4.54 (t, J = 7.0 Hz, 2H), 4.32 (d, J = 4.4 Hz, 1H), 3.82 (dd, J =
9.1, 3.0 Hz, 1H), 3.73 (s, 3H), 3.56 (dd, J = 9.1, 3.2 Hz, 1H), 3.12 (dd, J = 13.3, 6.5 Hz, 1H),
3.02 (ddd, J = 14.1, 13.1, 5.9 Hz, 2H), 2.84 (dd, J = 14.1, 7.2 Hz, 1H), 2.74 – 2.64 (m, 2H),
1.71 – 1.59 (m, 3H), 1.46 (s, 9H), 1.39 – 1.21 (m, 20H), 1.13 (s, 9H), 0.87 (t, J = 7.0 Hz,
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3H). 13C NMR (126 MHz, CDCl3) δ 170.56, 170.36, 155.36, 148.63, 121.30, 80.54, 73.75,
61.67, 53.85, 53.35, 52.62, 49.64, 34.44, 32.24, 32.07, 29.84, 29.82, 29.80, 29.72, 29.62,
29.55, 29.50, 29.47, 28.44, 27.42, 25.86, 22.84, 14.28. MS (ESI-TOF) for C33H61N5O6S [M
+H]+ Found 656.4403, Calculated 656.4415; [M+Na]+ Found 678.4223, Calculated
678.4235.
Synthesis of Compound 24: (S)-Methyl 2-((R)-2-acetamido-3-((2-(4-
tridecyl-1H-1,2,3-triazol-1-yl)ethyl)thio)propanamido)-3-hydroxypropanoate—
The global deprotection of compound 23 using TFA and further N-acetylation was carried
out similarly as described earlier (synthesis of 22) to furnish compound 24 as a white
solid. 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 7.8 Hz, 1H), 7.38 (s, 1H), 6.78 (d, J = 6.8
Hz, 1H), 5.21 (s, 1H), 4.92 (ddd, J = 14.2, 8.9, 4.1 Hz, 1H), 4.63 (ddd, J = 7.7, 4.6, 3.0 Hz,
1H), 4.61 – 4.52 (m, 2H), 4.03 (dd, J = 12.2, 3.7 Hz, 2H), 3.75 (s, 3H), 3.24 (ddd, J = 14.8,
5.9, 4.2 Hz, 1H), 3.07 (dd, J = 9.0, 4.7 Hz, 1H), 2.90 (dd, J = 14.5, 4.1 Hz, 1H), 2.72 (dd, J =
14.5, 9.1 Hz, 1H), 2.67 (dd, J = 8.5, 6.8 Hz, 2H), 2.03 (s, 3H), 1.73 – 1.54 (m, 2H), 1.39 –
1.17 (m, 20H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.40, 170.23,
169.96, 149.51, 121.78, 62.52, 55.79, 53.11, 52.67, 50.05, 36.03, 34.69, 32.06, 29.83, 29.81,
29.79, 29.69, 29.50, 29.48, 29.39, 29.37, 25.57, 23.31, 22.84, 14.28. MS (ESI-TOF) for
C26H47N5O5S [M+H]+ Found 542.3378, Calculated 542.3371; [M+Na]+ Found 564.3201,
Calculated 564.3190.
Synthesis of Compound 27: (S)-Methyl 2-((R)-2-acetamido-3-((2-(1-
hexadecyl-1H-1,2,3-triazol-4-yl)ethyl)thio)propanamido)-3-hydroxypropanoate
—To a solution of compound 17 (200 mg, 0.529 mmol) in dry DMF (5 mL) were added 4-
bromobut-1-yne (248 μL, 2.65 mmol) and triethylamine (147 μL, 1.06 mmol) and the
reaction mixture was heated to 90 °C for 1 h. After the completion of reaction, water (20
mL) was added to the reaction and the product obtained was extracted in EtOAc. The
organic layer was washed with water (10 mL × 3) and brine (10 mL), dried over anhydrous
sodium sulfate and the solvent was removed under reduced pressure to obtain the crude
product 25 as a white solid. The crude product was further washed with hexanes to remove
excess 4-bromobut-1-yne, dried and used as it is for the next step. To a stirred solution of
compound 25 (150 mg, 0.35 mmol) and 1-azidohexadecane (139 mg, 0.52 mmol) in THF (3
mL), were added CuSO4.5H2O (9 mg in 0.5 mL water, 0.035 mmol) and sodium ascorbate
(14 mg in 0.5 mL water, 0.07 mmol) and the reaction mixture was stirred at room
temperature overnight. After the completion of reaction, water (20 mL) was added and the
product obtained was extracted in EtOAc. The organic layer was washed with water (10 mL
× 2) and brine (10 mL), dried over anhydrous sodium sulfate and the solvent was removed
under reduced pressure to obtain the crude product 26. MS (ESI-TOF) for C36H67N5O6S [M
+H]+ Found 698.5075, Calculated 698.4885. The product 26 was used as it is for the next
step. The global deprotection using TFA and further N-acetylation was carried out similarly
as described earlier for synthesis of 22 to furnish compound 27 as white solid. 1H NMR
(500 MHz, CDCl3) δ 8.12 (d, J = 7.5 Hz, 1H), 7.38 (s, 1H), 6.93 (d, J = 7.2 Hz, 1H), 4.66
(td, J = 7.6, 4.5 Hz, 1H), 4.62 (dt, J = 7.3, 3.5 Hz, 1H), 4.29 (t, J = 7.3 Hz, 2H), 4.27 (bs,
1H), 4.02 (bs, 2H), 3.77 (s, 3H), 3.16 (ddd, J = 13.9, 7.7, 5.4 Hz, 1H), 3.09 (dd, J = 14.3, 4.4
Hz, 1H), 3.06 – 2.90 (m, 3H), 2.79 (dd, J = 14.3, 7.9 Hz, 1H), 2.06 (s, 3H), 1.92 – 1.82 (m,
2H), 1.30 (bs, 2H), 1.25 (bs, 20H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
170.61, 170.56, 170.36, 146.09, 121.88, 62.41, 55.56, 52.76, 52.68, 50.67, 35.02, 32.56,
32.07, 30.37, 29.85, 29.83, 29.80, 29.75, 29.68, 29.53, 29.51, 29.14, 26.64, 25.54, 23.37,
22.85, 14.29. MS (ESI-TOF) for C29H53N5O5S [M+H]+ Found 584.3889, Calculated
584.3840; [M+Na]+ Found 606.3692, Calculated 606.3660.
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Synthesis of Compound 30: (2S,5R)-methyl 5-amino-2-(hydroxymethyl)-4,11-
dioxo-10-oxa-7-thia-3,12-diazaoctacosan-1-oate—To a solution of compound 18
(100 mg, 0.237 mmol) in CH2Cl2 (1 mL) was added carbonyldiimidazole (58 mg, 0.355
mmol) and the reaction mixture was stirred at room temperature. Hexadecylamine (146 mg,
0.593 mmol) and DMF (1 mL) were added after 4 h and the reaction was kept stirring for 1
h. After the completion of reaction, water (10 mL) was added and the product obtained was
extracted in CH2Cl2. The organic layer was washed with water (10 mL × 3) and brine (10
mL), dried over anhydrous sodium sulfate and the solvent was removed under reduced
pressure to obtain the crude product. The residue was further purified by a flash
chromatography (5% MeOH/CH2Cl2 to yield product 29 (110 mg, 67%) as a white solid.
MS (ESI-TOF) for C35H67N3O8S [M+H]+ Found 690.4659, Calculated 690.4722; [M+Na]+
Found 712.4478, Calculated 712.4541. The global deprotection of compound 29 using TFA
resulted in compound 30 as a TFA salt in quantitative yield. 1H NMR (500 MHz, CDCl3) δ
8.53 (d, J = 7.6 Hz, 1H), 5.41 (t, J = 5.7 Hz, 1H), 4.72 – 4.63 (m, 1H), 4.36 (t, J = 6.5 Hz,
1H), 4.22 (ddd, J = 23.1, 11.5, 5.7 Hz, 2H), 3.89 (dt, J = 11.7, 7.2 Hz, 2H), 3.75 (s, 3H),
3.24 – 2.96 (m, 4H), 2.80 (t, J = 5.5 Hz, 2H), 1.46 (m, 2H), 1.25 (s, 26H), 0.88 (t, J = 7.0
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.45, 168.42, 156.76, 63.91, 61.89, 55.41, 52.94,
52.89, 41.32, 33.41, 32.08, 31.40, 29.94, 29.87, 29.86, 29.82, 29.77, 29.52, 26.97, 22.84,
14.28. MS (ESITOF) for C26H51N3O6S [M+H]+ Found 534.3524, Calculated 534.3571.
Synthesis of Compound 31: (2S,5R)-Methyl 5-acetamido-2-
(hydroxymethyl)-4,11-dioxo-10-oxa-7-thia-3,12-diazaoctacosan-1-oate—To a
solution of compound 30 (56 mg, 0.087 mmol) in CH2Cl2 (1 mL) were added pyridine (8
μL, 0.1 mmol) and acetic anhydride (9 μL, 0.1 mmol). The reaction mixture was stirred at
room temperature for 30 min and then concentrated. The residue was purified by a flash
chromatography (5% MeOH/CH2Cl2) to yield product 31 (32 mg, 64%) as a white solid. 1H
NMR (500 MHz, CDCl3) δ 7.48 (d, J = 7.6 Hz, 1H), 6.66 (d, J = 7.1 Hz, 1H), 5.25 (t, J = 5.5
Hz, 1H), 4.67 (dd, J = 14.1, 7.1 Hz, 1H), 4.63 (dd, J = 7.5, 3.6 Hz, 1H), 4.32 (dt, J = 12.2,
6.2 Hz, 1H), 4.25 (dt, J = 11.7, 6.0 Hz, 1H), 3.97 (q, J = 11.4 Hz, 2H), 3.79 (s, 3H), 3.31 (bs,
1H), 3.15 (dd, J = 13.4, 6.8 Hz, 2H), 2.96 (qd, J = 14.1, 6.6 Hz, 2H), 2.89 – 2.78 (m, 2H),
2.05 (s, 3H), 1.52 – 1.44 (m, 2H), 1.34 – 1.20 (m, 26H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 170.83, 170.68, 170.63, 156.79, 64.06, 62.80, 55.23, 52.91, 52.78,
41.31, 34.86, 32.07, 31.87, 29.98, 29.85, 29.81, 29.76, 29.72, 29.51, 29.46, 26.94, 23.29,
22.84, 14.28. MS (ESI-TOF) for C28H53N3O7S [M+H]+ Found 576.3594, Calculated
576.3677; [M+Na]+ Found 598.3414, Calculated 598.3496.
Synthesis of Compound 32: (2S,5R)-Methyl 5-((tert-butoxycarbonyl)amino)-2-
(tert-butoxymethyl)-4,11-dioxo-12-oxa-7-thia-3,10-diazaoctacosan-1-oate—To a
solution of compound 20 (100 mg, 0.238 mmol) in dry CH2Cl2 (5 mL) were added
triethylamine (50 μL, 0.356 mmol) and cetyl chloroformate (117 μL, 0.356 mmol) and the
reaction mixture was stirred at room temperature for 30 min. After the completion of
reaction, water (10 mL) was added to the reaction and the product obtained was extracted in
CH2Cl2. The organic layer was washed with water (10 mL × 2) and brine (10 mL), dried
over anhydrous sodium sulfate and the solvent was removed under reduced pressure to
obtain the crude product which was purified using column chromatography (50% EtOAc/
hexanes) to obtain compound 32 (120 mg, 74%). 1H NMR (500 MHz, CDCl3) δ 7.15 (d, J =
8.0 Hz, 1H), 5.47 (s, 1H), 5.26 (s, 1H), 4.66 (dt, J = 8.2, 3.1 Hz, 1H), 4.32 (s, 1H), 4.03 (t, J
= 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 3.0 Hz, 1H), 3.74 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H),
3.39 (d, J = 5.4 Hz, 2H), 2.97 (dd, J = 13.9, 5.4 Hz, 1H), 2.87 (dd, J = 13.8, 6.8 Hz, 1H),
2.80 – 2.65 (m, 2H), 1.63 – 1.54 (m, 2H), 1.45 (s, 9H), 1.33 – 1.23 (m, 26H), 1.14 (s, 9H),
0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.68, 170.52, 156.92, 155.44,
80.44, 73.73, 65.28, 61.78, 53.79, 53.30, 52.60, 40.15, 34.50, 32.73, 32.06, 29.84, 29.82,
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29.80, 29.75, 29.71, 29.50, 29.47, 29.16, 28.44, 27.42, 26.01, 22.83, 14.27. MS (ESI-TOF)
for C35H67N3O8S [M+Na]+ Found 712.4461, Calculated 712.4547.
Synthesis of Compound 33: (2S,5R)-Methyl 5-amino-2-(hydroxymethyl)-4,11-
dioxo-12-oxa-7-thia-3,10-diazaoctacosan-1-oate—To compound 32 (110 mg, 0.159
mmol) was added TFA (2 mL). The reaction mixture was stirred at room temperature for 30
min and then dried by blowing nitrogen through the solution. The residue was purified by a
flash chromatography (10% MeOH/CH2Cl2) to yield product 33 in quantitative yield. 1H
NMR (500 MHz, DMSO) δ 8.96 (d, J = 7.8 Hz, 1H), 8.09 (s, 2H), 7.98 (t, J = 5.7 Hz, 1H),
5.26 (t, J = 5.4 Hz, 1H), 4.47 – 4.41 (m, 1H), 4.02 (dd, J = 8.9, 4.6 Hz, 1H), 3.79 (dt, J =
10.4, 5.1 Hz, 1H), 3.65 (s, 3H), 3.64 – 3.60 (m, 1H), 3.24 (tt, J = 13.7, 7.0 Hz, 2H), 3.03 (dd,
J = 14.4, 4.5 Hz, 1H), 2.74 (dd, J = 14.4, 8.9 Hz, 1H), 2.65 (td, J = 6.6, 2.6 Hz, 2H), 2.06 (t,
J = 7.4 Hz, 2H), 1.51 – 1.44 (m, 2H), 1.32 – 1.18 (m, 24H), 0.85 (t, J = 6.9 Hz, 3H). 13C
NMR (126 MHz, DMSO) δ 172.57, 170.35, 167.92, 61.06, 54.76, 52.13, 51.68, 38.12,
35.41, 32.82, 31.36, 31.32, 29.08, 29.04, 28.98, 28.84, 28.73, 28.70, 25.28, 22.12, 13.99. MS
(ESI-TOF) for C26H51N3O6S [M+H]+ Found 534.3530, Calculated 534.3571; [M+Na]+
Found 556.3351, Calculated 556.3391.
Synthesis of Compound 34: (2S,5R)-Methyl 5-acetamido-2-
(hydroxymethyl)-4,11-dioxo-12-oxa-7-thia-3,10-diazaoctacosan-1-oate—To a
solution of compound 33 (60 mg, 0.093 mmol) in dichloromethane (2 mL) was added
pyridine (8 μL, 0.102 mmol) and acetic anhydride (10 μL, 0.102 mmol). The reaction
mixture was stirred at room temperature for 30 min and then concentrated. The residue was
purified by a flash chromatography (5% MeOH/CH2Cl2) to yield product 34. 1H NMR (500
MHz, CDCl3) δ 7.56 (d, J = 7.4 Hz, 1H), 6.75 (d, J = 6.7 Hz, 1H), 5.20 (d, J = 5.2 Hz, 1H),
4.74 – 4.58 (m, 2H), 4.10 – 3.89 (m, 4H), 3.79 (s, 3H), 3.42 (dd, J = 12.5, 6.2 Hz, 3H), 2.94
(d, J = 6.1 Hz, 2H), 2.83 – 2.67 (m, 2H), 2.05 (s, 3H), 1.66 – 1.53 (m, 2H), 1.36 – 1.20 (m,
26H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.87, 170.66, 157.61,
65.69, 62.77, 55.23, 52.90, 52.58, 40.34, 34.48, 32.92, 32.07, 29.85, 29.84, 29.81, 29.75,
29.71, 29.51, 29.45, 29.09, 26.00, 23.27, 22.84, 14.28. MS (ESI-TOF) for C28H53N3O7S [M
+H]+ Found 576.3602, Calculated 576.3677; [M+Na]+ Found 598.3416, Calculated
598.3496.
Synthesis of Compound 35: (2S,5R)-5-((tert-Butoxycarbonyl)amino)-2-(tert-
butoxymethyl)-4,11-dioxo-12-oxa-7-thia-3,10-diazaoctacosan-1-oic acid—To a
solution of compound 32 (100 mg, 0.145 mmol) in dichloroethane (2.5 mL) was added
trimethyltin hydroxide (79 mg, 0.435 mmol) and the reaction mixture was heated to reflux
for 6 h. After the completion of reaction, the solvent was removed under reduced pressure to
obtain the crude product which was purified using column chromatography (50% CH2Cl2/
EtOAc) to obtain compound 35 (72 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 7.23 (d, J =
6.8 Hz, 1H), 5.55 (d, J = 7.3 Hz, 1H), 5.28 (s, 1H), 4.70 – 4.60 (m, 1H), 4.34 (s, 1H), 4.04 (t,
J = 6.4 Hz, 2H), 3.90 (dd, J = 9.0, 3.5 Hz, 1H), 3.57 (dd, J = 8.5, 4.9 Hz, 1H), 3.36 (dd, J =
16.2, 10.1 Hz, 2H), 2.93 (qd, J = 13.9, 6.2 Hz, 2H), 2.78 – 2.61 (m, 2H), 1.64 – 1.54 (m,
2H), 1.45 (s, 9H), 1.35 – 1.22 (m, 26H), 1.19 (s, 3H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 172.38, 171.01, 157.13, 155.65, 80.69, 74.63, 65.46, 61.26, 53.86,
52.90, 40.17, 34.31, 32.65, 32.07, 29.85, 29.81, 29.76, 29.72, 29.51, 29.48, 29.15, 28.44,
27.45, 26.01, 22.84, 14.28. MS (ESI-TOF) for C34H65N3O8S [M+Na]+ Found 698.4272,
Calculated 698.4385.
Synthesis of Compound 36: tert-Butyl hexadecyl ((8S,11R)-8-(tert-
butoxymethyl)-2-methyl-7,10-dioxo-13-thia-2,6,9-triazapentadecane-11,15-
diyl)dicarbamate—To a solution of acid 35 (563 mg, 0.833 mmol) and N1,N1-
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dimethylpropane-1,3-diamine (115 μL, 0.916 mmol) in DMF (5 mL) were added
triethylamine (232 μL, 1.67 mmol) and N-hydroxybenzotriazole (HOBt, 56 mg, 0.417
mmol). The reaction mixture was cooled to 0 °C and EDCI (258 mg, 1.67 mmol) was added
after 30 min. The resulting mixture was stirred at room temperature overnight. After the
completion of reaction, water (20 mL) was added to the reaction and the product obtained
was extracted in EtOAc. The organic layer was washed with water (10 mL × 3) and brine
(10 mL), dried over anhydrous sodium sulfate and the solvent was removed under reduced
pressure to obtain the crude product which was purified using column chromatography (10%
MeOH/CH2Cl2) to obtain compound 36 (530 mg, 84%). MS (ESITOF) for C39H77N5O7S
[M+H]+ Found 760.5486, Calculated 760.5616.
Synthesis of Compound 38: Hexadecyl ((8S,11R)-11-acetamido-8-
(hydroxymethyl)-2-methyl-7,10-dioxo-13-thia-2,6,9-triazapentadecan-15-
yl)carbamate—To compound 36 (521 mg, 0.685 mmol) was added TFA (5 mL). The
reaction mixture was stirred at room temperature for 30 min and then dried by blowing
nitrogen through the solution. The crude product was used directly for the next step. To a
solution of the crude intermediate 37 in CH2Cl2 (5 mL) were added pyridine (61 μL, 0.754
mmol) and acetic anhydride (71 μL, 0.754 mmol). The reaction mixture was stirred at room
temperature for 30 min and then concentrated. The residue was purified by a flash
chromatography (20% MeOH/CH2Cl2) to give product 38 as a white solid. 1H NMR (500
MHz, MeOD) δ 4.49 (dd, J = 8.0, 5.9 Hz, 1H), 4.28 (t, J = 5.0 Hz, 1H), 4.02 (t, J = 6.6 Hz,
2H), 3.88 (dd, J = 11.0, 5.1 Hz, 1H), 3.79 (dd, J = 11.0, 5.0 Hz, 1H), 3.40 – 3.31 (m, 4H),
3.17 – 3.10 (m, 2H), 3.01 (dd, J = 13.7, 5.7 Hz, 1H), 2.89 (s, 6H), 2.83 (dd, J = 13.7, 8.1 Hz,
1H), 2.68 (td, J = 13.5, 6.6 Hz, 2H), 2.03 (s, 3H), 1.93 (dt, J = 13.2, 6.4 Hz, 2H), 1.68 – 1.55
(m, 2H), 1.42 – 1.25 (m, 26H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ
173.97, 173.33, 173.25, 159.35, 66.05, 62.44, 57.50, 56.40, 54.92, 43.59, 41.16, 36.65,
33.94, 33.09, 33.02, 30.80, 30.78, 30.72, 30.49, 30.44, 30.23, 27.00, 25.97, 23.75, 22.48,
14.45. MS (ESI-TOF) for C32H63N5O6S [M+H]+ Found 646.4426, Calculated 646.4572.
TLR2-specific NF-κB induction
The induction of NF-κB in a human TLR2-specific reporter gene assay was quantified using
HEK-Blue™ cells as previously described by us.30,36,52 Occupancy of TLR2 by cognate
ligands leads to nuclear translocation of NF-κB in a MyD88-dependent manner,59–61 and
consequent transactivation of the secreted alkaline phosphatase (seAP) reporter gene.
Extracellular seAP in the supernatant is proportional to NF-κB induction, and was quantified
spectrophotometrically.
Immunoassays for cytokines and chemokines
Fresh human peripheral blood mononuclear cells (hPBMC) were isolated from human blood
obtained by venipuncture with informed consent and as per institutional guidelines on
Ficoll-Hypaque gradients as described elsewhere.62 Aliquots of PBMCs (105 cells in 100
μL/well) were stimulated for 12 h with graded concentrations of test compounds.
Supernatants were isolated by centrifugation, and were assayed in duplicates for 41
chemokines and cytokines (EGF, Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-
CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1ra,
IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1, MCP-3, MDC
(CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGFAB/BB, RANTES, TGFα, TNF-α, TNF-β,
VEGF, sCD40L) using a magnetic bead-based multiplexed assay kit (Milliplex MAP
Human Cytokine/Chemokine kit). Data were acquired and processed on a MAGPIX
instrument (EMD Millipore, Billerica, MA) with an intra-assay coefficients of variation
ranging from 4–8% for the 41 analytes.
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CD11b upregulation was determined by flow cytometry using protocols published by us
previously,41 modified for rapid-throughput using an automated liquid-handling system.
Briefly, heparin-anticoagulated whole blood samples were obtained by venipuncture from
healthy human volunteers with informed consent and as per guidelines approved by the
University of Kansas Human Subjects Experimentation Committee. Serial dilutions of 38
(as well as 2 and LPS, used as reference compounds) were performed using a Bio-Tek
Precision 2000 XS liquid handler in sterile 96-well polypropylene plates, to which were
added 100 μL aliquots of anticoagulated whole human blood. Negative (fRPMI) controls
were included in each experiment. The plates were incubated at 37 °C for 1 h. Following
incubation, 10 μL of each fluorochrome-conjugated antibody (CD11b-PE, CD14-APC,
Becton-Dickinson Biosciences, San Jose, CA) were added to each well with a liquid
handler, and incubated at 4 °C in the dark for 30 min. Following staining, erythrocytes were
lysed and leukocytes fixed by mixing 200 μL of the samples in 2 mL prewarmed Whole
Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA) in 96 deep-well
plates. After washing the cells twice at 200 g for 8 minutes in saline, the cells were
transferred to a 96-well plate. Flow cytometry was performed using a BD FACSArray
instrument with acquisition on 100,000 gated events. Granulocytes were gated by forward-
and side-scatter, while monocytes were gated on the basis of CD14−APC staining.
Immunization and safety evaluation in rabbits
All experiments were performed at Harlan Laboratories (Indianapolis, IN) in accordance
with institutional guidelines (University of Kansas IACUC permit # 119-06). In experiments
designed to evaluate the adjuvanticity of 12, cohorts of adult female New Zealand White
rabbits were immunized intramuscularly in the flank region with either 100 μg of bovine α-
lactalbumin in 0.2 mL saline (unadjuvanted control), or 100 μg of bovine α-lactalbumin plus
100 μg of 12 in 0.2 mL saline. The adjuvantic property of 38 (100 μg/dose) was evaluated
using CRM197 as antigen (10 μg/dose). Pre-immune test-bleeds were first obtained via
venipuncture of the marginal vein of the ear. Animals were immunized on Days 1, 15 and
28. A test bleed was performed on Day 25 and a final test-bleed was performed via the
marginal vein of the ear on Day 38. Sera were stored at −80 °C until used. Antigen-specific
ELISAs were performed in 384- well format using automated liquid handling methods as
described by us.34,53 Safety evaluation in rabbit models included examination of clinical
hematology parameters (total and differential leukocyte counts, enumeration of band-forms
(immature neutrophils), hemoglobin, and mean corpuscular hemoglobin), as well as core-
temperature monitoring. Cohorts of animals (n=3 per group) received either 38 (100 μg/
dose), LPS (1 μg/dose, positive control) or vehicle (saline) formulated in sterile saline
without any excipients in a volume of 0.5 mL, administered as an intravenous bolus in the
marginal vein of the ear. Blood was obtained at 0h (pre-challenge), and at 2h and 6h via
venipuncture on the contralateral ear. Core temperature was monitored by rectal thermistor
probes connected to a temperature logging device as described by us.31
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CD cluster of differentiation
DCs dendritic cells
EC50 Halfmaximal effective concentration for agonism
ESI-TOF Electrospray ionization-time of flight
HEK Human embryonic kidney
Ig Immunoglobulin
IL Interleukin
MPL 3-O-desacyl-4′-monophosphoryl lipid A
MCP monocyte chemotactic protein
mDC myeloid dendritic cell
MHC Major histocompatibility complex
NF-κB Nuclear factor-κB
pDC plasmacytoid dendritic cell
SAR Structure activity relationship
seAP secreted alkaline phosphatase
Th1 Helper T lymphocyte, type 1
Th2 Helper T lymphocyte, type 2
TLR Toll like receptor
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Structures of the human/murine TLR2 agonists (1, 2) human TLR2-specific low potency (3)
and high potency (4) lipopeptides.
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Dose-response profiles of TLR2-agonistic activities of water soluble derivatives of 4
(Compounds 10-15) in reporter gene assays specific for human TLR2 (top) and murine
TLR2 (bottom). Compounds 2 and 4 were used as comparators. Means and s.d. on
quadruplicate samples are shown.
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Rise in antigen-specific IgG levels after primary and secondary immunizations in rabbits
(n=4 per cohort) receiving 100 μg/dose of bovine α-lactalbumin, adjuvanted with 100 μg/
dose of 12, formulated in saline, with no excipients.
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Dose-response profiles of human TLR2-specific agonistic activities of the triazole, amide
and carbamate analogues of 4 in hTLR-specific reporter gene assays. Means and s.d. on
quadruplicate samples are shown.
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Induction of select chemokines by 38 in human PBMCs quantified by 41-plex
immunoassays. LPS was used as reference. Means of duplicates of a representative
experiment are shown. Chemokine concentrations were below detection limits in negative
controls, and are not shown.
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CD11b upregulation (dose-response profiles) in granulocytes (left) and monocytes (right)
induced by 38 in human whole blood. Compound 2 and LPS were used as comparator/
positive controls. Insets show flow cytometric gating strategies (forward- and side-scatter
for granulocytes, left) and CD14+ cells for monocytes (right).
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Panels A and B: Effect of a single intravenous bolus injection of 38 (100 μg/dose) and LPS
(1 μg/dose) on total leukocyte and lymphocyte counts in peripheral blood in rabbits (n=3 per
cohort). Gray regions indicate normal values. Panel C: Pyrogenicity in rabbits (n=3 per
cohort) administered either 38 (100 μg/dose) and LPS (1 μg/dose). Core temperature was
monitored using rectal thermistor probes. One animal in each cohort was invalidated due to
unforeseen problems: coagulated blood samples (A, B) or expulsion of temperature probes
(C).
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Anti-diphtheria toxoid (CRM197) IgG titers in rabbits (n=5 per cohort) immunized with 10
μg/dose of CRM197 in saline (controls), or CRM197 adjuvanted with 100 μg/dose of 38.
Box-plots of immune titers yielding absorbance values of 1.0 are shown for the individual
samples. Means and medians of titers are represented by □ and — symbols within the box,
respectively, and the X symbols indicate the 1% and 99% percentile values.
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Syntheses of the water soluble analogue 10.
Reagents and Conditions: i. (a) Boc2O, Et3N, H2O (b) H-Lys(Fmoc)-OMe.HCI, EDCI,
HOBt, Pyridine, DMF; ii. (a) HCI, dioxane (b) Ac2O, Pyridine, DCM; iii. Bu3P, CH2CI2,
H2O; iv. 2-lodoethanol, K2CO3, DMF; v. C15H31COCI, Pyridine, DCM; vi. Piperazine
polymer bound, DMF.
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Attempts towards new water soluble monoacyl analogues.
Reagents and Conditions: i. N,N′-Di-Boc-L-lysine, EDCI, NMM, DMAP, DCM; ii. HCI,
dioxane; iii. SO3-Pyridine, pyridine; iv. Succinic anhydride, Et3N, THF; v. nicotinic acid,
EDCI, DMAP, NMM.
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Synthesis of amide derivative of 4.
Reagents and Conditions: i. (a) Boc2O, Et3N, H2O (b) H-Ser(tBu)-OMe.HCl, EDCI, HOBt,
Et3N, DMF; ii. Bu3P, CH2Cl2; iii. 2-Iodoethanol, Et3N, DMF; iv. (a) MsCl, Et3N, DCM (b)
NaN3, DMF; v. PPh3, THF, H2O; vi. C15H31COCl, DCM; vii. (a) TFA (b) Ac2O, Et3N,
DCM.
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Synthesis of 1,2,3-triazole derivatives of 4.
Reagents and Conditions: i. pentadec-1-yne, CuSO4, sodium ascorbate, THF, H2O. ii. (a)
TFA (b) Ac2O, pyridine, DCM; iii. 4-bromobut-1-yne, Et3N, DMF; iv. 1-azidohexadecane,
CuSO4, sodium ascorbate, THF, H2O.
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Synthesis of carbamate derivatives of 4.
Reagents and Conditions: i. CDI, DCM; ii. C16H33NH2, DCM; iii. TFA; iv. Ac2O, pyridine,
DCM; v. cetyl chloroformate, Et3N, DCM.
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Synthesis of the water soluble carbamate derivative 38.
Reagents and Conditions: i. (CH3)3SnOH, DCE; ii. N1,N1-dimethylpropane-1,3-diamine,
EDCI, HOBT, NMM, DMF; iii. TFA; iv. Ac2O, Et3N, DCM.
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Table 1
EC50 values of compounds in human TLR2-specific reporter gene assay.




















Salunke et al. Page 36







J Med Chem. Author manuscript; available in PMC 2014 July 25.
